At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study on the Efficacy and Safety of CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients Who Have Completed Adjuvant Anti-HER2 Targeted Therapy"
In Brief
A Phase 3 clinical trial evaluating Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) and Standard endocrine therapy combined with CDK4/6 Inhibitor for Breast Cancer and Adjuvant Therapy. Currently recruiting, targeting 1,903 participants across 1 site.
Detailed Summary
This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. Building upon anti-HER2 targeted therapy combined with endocrine therapy, the addition of CDK4/6 inhibitors has demonstrated greater clinical benefits for advanced TPBC patients. This study aims to investigate the efficacy and safety of CDK4/6 inhibitor combination with standard adjuvant endocrine therapy in HR+/HER2+ early breast cancer patients.
Study Details
Timeline
Interventions
Standard endocrine therapy
CDK4/6 inhibitor therapy for 2 years in combination with standard endocrine therapy